Cipla Vs Dr. Reddy’s Laboratories – Financials, Future Plans & More
Trade Brains
OCTOBER 6, 2023
Following global demand, Cipla has deepened its portfolio for the US markets with continued traction in the respiratory franchise and expansion of its peptide portfolio with increased market share in the Company’s first Lanreotide injection. This portfolio is boosted by the successful launch of gRevlimid.
Let's personalize your content